Wellington Management Group’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.7M Buy
565,442
+103,796
+22% +$500K ﹤0.01% 1550
2026
Q2
$2.22M Buy
461,646
+20,722
+5% +$91K ﹤0.01% 1606
2026
Q1
$1.98M Sell
440,924
-33,437
-7% -$146K ﹤0.01% 1551
2025
Q4
$2.28M Sell
474,361
-39,722
-8% -$179K ﹤0.01% 1569
2025
Q3
$2.33M Sell
514,083
-17,468
-3% -$64.2K ﹤0.01% 1594
2025
Q2
$1.64M Buy
531,551
+21,042
+4% +$69.9K ﹤0.01% 1622
2025
Q1
$1.78M Sell
510,509
-2,793
-0.5% -$9.31K ﹤0.01% 1588
2024
Q4
$1.68M Buy
513,302
+16,484
+3% +$60.6K ﹤0.01% 1611
2024
Q3
$1.91M Buy
496,818
+21,807
+5% +$83.6K ﹤0.01% 1550
2024
Q2
$1.47M Buy
475,011
+23,706
+5% +$71.1K ﹤0.01% 1584
2024
Q1
$1.16M Buy
+451,305
New +$1.17M ﹤0.01% 1652
2023
Q2
– Sell
-279,832
Closed -$848K – 1796
2023
Q1
$848K Sell
279,832
-129,672
-32% -$366K ﹤0.01% 1699
2022
Q4
$954K Sell
409,504
-24,060
-6% -$57.6K ﹤0.01% 1640
2022
Q3
$828K Sell
433,564
-71,700
-14% -$169K ﹤0.01% 1693
2022
Q2
$1.37M Hold
505,264
– – ﹤0.01% 1612
2022
Q1
$1.51M Buy
505,264
+225,175
+80% +$689K ﹤0.01% 1658
2021
Q4
$1.09M Buy
+280,089
New +$1.09M ﹤0.01% 1787

Other funds holding ABUS

Wellington Management Group's ABUS Position: Q3 2026 in Review

Wellington Management Group increased its Arbutus Biopharma (ABUS) stake by 22% in Q3 2026, buying an estimated $500K and bringing the position to 565,442 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

Wellington Management Group first reported a position in ABUS in Q4 2021 and has held it in 17 quarters since. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Wellington Management Group held 565,442 shares of Arbutus Biopharma worth $2.7M as of Q3 2026.
  • Wellington Management Group bought 103,796 Arbutus Biopharma shares in Q3 2026, an estimated $500K.
  • Arbutus Biopharma made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1550 holding.
  • Wellington Management Group first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 17 quarters since.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.